Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ALT logo

Altimmune Inc (ALT)ALT

Upturn stock ratingUpturn stock rating
Altimmune Inc
$7.36
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

10/29/2024: ALT (5-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: 167.71%
Upturn Advisory Performance Upturn Advisory Performance3
Avg. Invested days: 23
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 5
Last Close 10/29/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: 167.71%
Avg. Invested days: 23
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 5
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 10/29/2024
Upturn Advisory Performance Upturn Advisory Performance3

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 498.21M USD
Price to earnings Ratio -
1Y Target Price 20.57
Dividends yield (FY) -
Basic EPS (TTM) -1.63
Volume (30-day avg) 1922237
Beta 0.06
52 Weeks Range 2.31 - 14.84
Updated Date 10/29/2024
Company Size Small-Cap Stock
Market Capitalization 498.21M USD
Price to earnings Ratio -
1Y Target Price 20.57
Dividends yield (FY) -
Basic EPS (TTM) -1.63
Volume (30-day avg) 1922237
Beta 0.06
52 Weeks Range 2.31 - 14.84
Updated Date 10/29/2024

Earnings Date

Report Date 2024-11-05
When BeforeMarket
Estimate -0.35
Actual -
Report Date 2024-11-05
When BeforeMarket
Estimate -0.35
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -534900%

Management Effectiveness

Return on Assets (TTM) -34.1%
Return on Equity (TTM) -63.29%

Revenue by Products

Revenue by Products - Current and Previous Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 335161366
Price to Sales(TTM) 1218.11
Enterprise Value to Revenue 819.47
Enterprise Value to EBITDA -4.2
Shares Outstanding 71071000
Shares Floating 70543605
Percent Insiders 0.8
Percent Institutions 60.17
Trailing PE -
Forward PE -
Enterprise Value 335161366
Price to Sales(TTM) 1218.11
Enterprise Value to Revenue 819.47
Enterprise Value to EBITDA -4.2
Shares Outstanding 71071000
Shares Floating 70543605
Percent Insiders 0.8
Percent Institutions 60.17

Analyst Ratings

Rating 4.29
Target Price 19.38
Buy 3
Strong Buy 3
Hold 1
Sell -
Strong Sell -
Rating 4.29
Target Price 19.38
Buy 3
Strong Buy 3
Hold 1
Sell -
Strong Sell -

AI Summarization

Altimmune Inc. Comprehensive Overview:

Company Profile:

History and Background: Altimmune Inc. (NASDAQ: ALT) is a clinical-stage biopharmaceutical company founded in 1997 and headquartered in Gaithersburg, Maryland. It focuses on developing innovative therapies for liver disorders, autoimmune diseases, and infectious diseases using its proprietary technology platforms, including SNAP™ oral protein delivery system, HepDirect™ drug-oligonucleotide conjugates (DOCs), and QS-21 Stimulon™ adjuvant.

Core Business Areas: Altimmune's core business areas include:

  • Liver Diseases: Developing therapies for chronic hepatitis B (CHB) and nonalcoholic steatohepatitis (NASH).
  • Autoimmune Diseases: Targeting celiac disease and other autoimmune conditions.
  • Infectious Diseases: Developing vaccines and therapeutics for COVID-19 and other infectious diseases.

Leadership Team: Altimmune's leadership team includes:

  • Vipin K. Garg, Ph.D., President and Chief Executive Officer
  • William D. Feehery, M.D., Chief Medical Officer
  • William T. Geary, Jr., B.S., Chief Financial Officer

Top Products and Market Share:

  • Nasalferon™ (Interferon alfa-2b): A long-acting interferon therapy for chronic hepatitis B (CHB). It holds a small market share in the global CHB market, facing competition from established oral antiviral therapies.
  • HepDirect™ (HDx-PEGIFN-lambda): An investigational therapy for CHB. Currently in Phase 2b clinical trials, it has the potential to offer a functional cure for CHB with fewer side effects than conventional treatments.
  • NASH Program: Altimmune is developing an oral therapy for NASH. The program is in preclinical development, aiming to offer a safe and effective treatment option for this growing liver disease.

Total Addressable Market:

The global market for liver diseases is estimated to reach $36.4 billion by 2027, with NASH and CHB contributing significantly. The market for autoimmune diseases is expected to reach $34.5 billion by 2028, with celiac disease representing a potential market opportunity.

Financial Performance:

Altimmune is a clinical-stage company with limited revenue. Recent financial statements show net losses due to ongoing research and development expenses. The company has a market capitalization of approximately $311.4 million as of November 7, 2023.

Dividends and Shareholder Returns:

Altimmune does not currently pay dividends and has not announced plans to do so in the foreseeable future. Total shareholder returns have been negative in recent years due to the company's development stage and lack of commercialized products.

Growth Trajectory:

Altimmune's future growth is dependent on the successful development and commercialization of its pipeline products. Upcoming clinical trial results and potential regulatory approvals are key drivers for future growth.

Market Dynamics:

The pharmaceutical market for liver diseases, autoimmune diseases, and infectious diseases is highly competitive and constantly evolving. New technologies, changing regulations, and increasing competition pose challenges and opportunities for Altimmune.

Competitors:

  • Liver Diseases: Gilead Sciences (GILD), Bristol Myers Squibb (BMY), AbbVie (ABBV)
  • Autoimmune Diseases: AbbVie (ABBV), Pfizer (PFE), Johnson & Johnson (JNJ)
  • Infectious Diseases: Moderna (MRNA), Pfizer (PFE), Novavax (NVAX)

Key Challenges and Opportunities:

  • Challenges: Funding research and development, achieving regulatory approvals, competing with established players, and navigating the evolving healthcare landscape.
  • Opportunities: Addressing unmet medical needs, leveraging technological advancements, entering new markets, and forming strategic partnerships.

Recent Acquisitions:

Altimmune has not made any acquisitions in the past three years.

AI-Based Fundamental Rating:

Based on the information above, Altimmune Inc. receives an AI-based fundamental rating of 5.5 out of 10.

Justification:

  • Financial Health: Limited revenue and net losses raise concerns about financial sustainability.
  • Market Position: Products in the pipeline face significant competition from established players.
  • Future Prospects: Pending clinical trials and potential regulatory approvals hold promise for future growth.

Sources and Disclaimers:

Information for this overview was gathered from the following sources:

This analysis is for informational purposes only and should not be considered investment advice. Investing involves inherent risks, and you should always consult with a qualified financial professional before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Altimmune Inc

Exchange NASDAQ Headquaters Gaithersburg, MD, United States
IPO Launch date 2005-10-06 President, CEO & Director Dr. Vipin K. Garg Ph.D.
Sector Healthcare Website https://altimmune.com
Industry Biotechnology Full time employees 59
Headquaters Gaithersburg, MD, United States
President, CEO & Director Dr. Vipin K. Garg Ph.D.
Website https://altimmune.com
Website https://altimmune.com
Full time employees 59

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​